Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry

Hurk, Corina van den; Eckel, Renate; Poll‐Franse, Lonneke V. van de; Coebergh, Jan Willem; Nortier, J.W.R.; Hölzel, Dieter; Breed, W.P.M.; Engel, Jutta

doi:10.1007/s10549-011-1372-y

Cited by 48 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The oldest cohort from 1978 to 1984 showed the best survival with the lowest prior exposure to adjuvant treatment. In a cooperation between the Munich Cancer Registry and Leiden University, these results were confirmed for the interval between 1978 and 2008 [19], i.e. unfavorable changes in the pattern of metastases, and, again, no improvements in survival of the patients after occurrence of metastases.…”

Section: Discussionmentioning

confidence: 78%

“…An explanation for these unsatisfying results may be that the increased use of adjuvant systemic treatment has less effect on the highly lethal liver and central nervous system (CNS) metastases than on bone metastases. The multivariate analyses revealed a 20% higher hazard (p = 0.02) of dying within 5 years following metastases in the last (2003-2008) vs. the first (1978-1983) cohort [19]. However, adjuvant systemic treatment contributed decisively to the overall prevention of metastases and, therefore, generally improved OS of breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Kleeberg

Fink²,

Tessen³

et al. 2013

Oncol Res Treat

View full text Add to dashboard Cite

Background: Adjuvant treatment concepts have improved the 10-year cure rate of breast and colon cancer, but new treatments for metastatic disease have yielded only incremental benefit. If treatments for disseminated cancer were actually prolonging life rather than only increasing remission rates, this effect should have been documented over the last 30+ years. However, published data concerning advances in treatment for disseminated cancer have been contradictory. Patients and Methods: To add data-based information, we analyzed 2 sources: a regional population-based cancer registry (Hamburgisches Krebsregister, HKR), and a research cancer registry (Projektgruppe Internistische Onkologie, PIO). We compared the survival of several thousand patients with metastatic disease who received treatment only after dissemination with that of patients who received initial adjuvant therapy. Results: After adjuvant treatment, survival in patients with disseminated breast cancer is up to a third shorter than that of patients without adjuvant therapy. Conclusions: In accordance with published evidence, we conclude that ineffective adjuvant treatment shortens survival after documentation of metastatic disease. This is probably due to the elimination of chemo-sensitive tumor cells or to the induction of resistance in remaining micrometatases. This negative effect on survival after dissemination has been shown clearly for breast cancer and is also probable for cancer of the colon and other sites.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Kleeberg

Fink²,

Tessen³

et al. 2013

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…The potential risk of scalp cooling lies in the protection of scalp metastasis from the effects of chemotherapy. However, that potential risk has, to date, been proved in only 2 patients 5 . Both of those patients had hematologic malignancies which, based on the published report, are regarded as a contraindication to scalp cooling.…”

Section: Introductionmentioning

confidence: 99%

Sensor-Controlled Scalp Cooling to Prevent Chemotherapy-Induced Alopecia in Female Cancer Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Resuspend cells in DMEM and centrifuge for 5 min at 1200 rpm (300 × g). 4. Once the supernatant is discarded, resuspend cells again in sterile PBS.…”

Section: Cell Harvestmentioning

confidence: 99%

“…Van de Hurk and colleagues [ 4 ] published a 30-year follow-up study with more than 33,000 patients, in which 60 % of breast cancer patients developed metastasis to distant organs with the central nervous system being one of the sites with higher incidence. Moreover, Patricia Steeg and colleagues [ 5 ] showed in a study of more than 1000 breast cancer patients that 15 % developed a single metastasis in the brain.…”

mentioning

confidence: 99%

Mouse Models of Brain Metastasis for Unravelling Tumour Progression

Soto

Sibson

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Secondary tumours in the brain account for 40 % of triple negative breast cancer patients, and the percentage may be higher at the time of autopsy. The use of in vivo models allow us to recapitulate the molecular mechanisms potentially used by circulating breast tumour cells to proliferate within the brain.Metastasis is a multistep process that depends on the success of several stages including cell evasion from the primary tumour, distribution and survival within the blood stream and cerebral microvasculature, penetration of the blood-brain barrier and proliferation within the brain microenvironment. Cellular adhesion molecules are key proteins involved in all of the steps in the metastatic process. Our group has developed two different in vivo models to encompass both seeding and colonisation stages of the metastatic process: (1) haematogenous dissemination of tumour cells by direct injection into the left ventricle of the heart, and (2) direct implantation of the tumour cells into the mouse brain.This chapter describes, in detail, the practical implementation of the intracerebral model, which can be used to analyse tumour proliferation within a specific area of the central nervous system and tumour-host cell interactions. We also describe the use of immunohistochemistry techniques to identify, at the molecular scale, tumour-host cell interactions, which may open new windows for brain metastasis therapy.

show abstract

Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry

Cited by 48 publications

References 39 publications

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Sensor-Controlled Scalp Cooling to Prevent Chemotherapy-Induced Alopecia in Female Cancer Patients

Mouse Models of Brain Metastasis for Unravelling Tumour Progression

Contact Info

Product

Resources

About